Relugolix in Monotherapy and Combined Therapy for the Treatment of Uterine Diseases and Its Effects on Bones: A Systematic Review.
Background: Uterine fibroids (UFs) and endometriosis are gynecological conditions that significantly increase morbidity among women of reproductive age. Relugolix, a novel gonadotropin-releasing hormone receptor antagonist, is approved in combined therapy …
Clinical significance of the CXCL6-CXCR1/CXCR2 chemokine signaling pathway in the peritoneal fluid of patients with endometriosis.
Endometriosis is the presence of endometrial tissue outside the uterine cavity with an accompanying chronic inflammatory process. The etiology of the disease is still not fully understood. An important role …